Acetaminophen Under Scrutiny In California For Prop 65 Requirements
Executive Summary
California extends deadline for data from cancer bioassays, epidemiological studies and genotoxicity tests for review of acetaminophen as a Prop 65 chemical due to carcinogenic potential. Deadline extended to May 29 in response to Consumer Healthcare Products Association request.
You may also be interested in...
US Health Market In 2019: Unfinished Business Leaves Lasting Impression
Examples of unfinished business from 2019 include no legislation passed to reform OTC monograph program; FDA putting off until May the planned publication of an NPRM to allow firms to submit OTC NDAs with extra-label information to help guide consumers' self-selection; and no OTC naloxone for opioid overdose approved even after FDA's unprecedented step of developing model DFLs sponsors could use for their own label comprehension studies.
Acetaminophen Could Have Exemption ‘Qualifications’ If Added To Prop 65
If acetaminophen is added to California's Prop 65 list, it would likely be a qualified listing, requiring OTC marketers only warn consumers under special circumstances, says a consumer products lawyer. Listing could spur argument between stakeholders and the state over FDA labeling pre-emption.
Prop 65 Proposal Stirs Retailers To Request Manufacturers' Guarantees
California Prop 65 amendment has retailers asking manufacturers for unrealistic guarantees that no products contain any Prop 65 chemicals, says Clif Bar & Co. Chief Counsel Amy Norris. Manufacturers should develop standard response to retailers' myriad requests and develop a plan to address any issues that could arise.